Summary: An open-labeled, dose-escalation phase 1 trial of Wilms tumor 1 (WT1) vaccine and gemcitabine (GEM) combination therapy for patients with advanced pancreatic cancer or biliary tract cancer was performed. The primary end point was evaluation of toxicity, safety, and optimal immunologic dose of vaccine. Human leukocyte antigen (HLA)-A 0201, HLA-A 0206, and/or HLA-A 2402-positive patients with inoperable advanced pancreatic or biliary tract cancer who had not previously been treated with GEM were eligible for this study. Six doses of GEM and 4 doses of WT1 peptide (1 or 3 mg) emulsified in Montanide adjuvant were administered over 2 months. Twenty-five patients (13 male and 12 female) were enrolled. Nine patients had inoperable advanced pancreatic cancer, 8 had gallbladder cancer, 4 had intrahepatic, and 4 had extrahepatic bile duct cancer. The adverse events were comparable to those with GEM alone. Delayed-type hypersensitivity test was positive after vaccination in 2 patients, and WT1-specific T cells in peptide-stimulated culture were detected by tetramer assay in 59% (13 of 22) of patients. The disease control rate at 2 months was 89% for pancreatic cancer and 50% for biliary tract cancer. With a median follow-up time of 259 days, the median survival time for biliary tract cancer was 288 days, and that for pancreatic cancer was 259 days. Although objective clinical efficacy was not apparent, the safety of WT1 vaccine and GEM combination therapy was confirmed in this study.
A s Wilms tumor 1 (WT1) protein is overexpressed in various types of cancer cell, [1] [2] [3] [4] [5] [6] it is an attractive candidate for cancer immunotherapy. [7] [8] [9] [10] [11] WT1 has recently been ranked as the number 1 antigen in the cancer antigen prioritization project sponsored by the National Cancer Institute.
12 WT1 peptide-based immunotherapy has been reported for various cancers, including leukemia, myelodysplastic syndromes, lung cancer, renal cell cancer, breast cancer, glioblastoma, and gynecologic cancer. [13] [14] [15] [16] [17] In this study, we administered a WT1 peptide vaccine combined with chemotherapy in pancreatic cancer and biliary cancer, as overexpression of WT1 is seen in 65% to 75% of these disorders. 5, 6 Moreover, the observation that WT1 protein is present in the cytoplasm of pancreatic ductal adenocarcinoma cells in the majority of cases 5 has encouraged clinical trials of WT1-based immunotherapy.
At present, surgery is the only radical therapeutic option for pancreatic and biliary tract cancers. In addition, gemcitabine (GEM) has been a key drug in chemotherapy for advanced pancreatic cancer resulting in improved survival and clinical benefits with GEM as a first-line therapy. 18 Combination of GEM with other agents is one promising avenue for improving the efficacy of treatment for advanced pancreatic cancer. In fact, a recent randomized phase 3 study of the combination of GEM/erlotinib showed a statistically significant survival benefit in comparison with GEM alone in patients with advanced pancreatic cancer, 19 although there is no worldwide consensus. Furthermore, advanced biliary tract cancer is often treated with GEM 20 and combination therapy with cisplatin has been shown to have survival benefits when compared with GEM monotherapy. 21 Nevertheless, the ultimate effects of chemotherapy alone in pancreatic cancer and biliary tract cancer remain limited, with long-term survival being very rare. 20, 22 The combination of GEM with immunotherapy is therefore attractive, as GEM does not suppress immunologic cells and increases the number of dendritic cells, which serve as antigen-presenting cells. To date, only 1 clinical trial of immunotherapy on pancreatic cancer using a personalized peptide has been reported, 23 and this study is the first reported clinical trial of the combination of WT1 vaccine and GEM chemotherapy.
MATERIALS AND METHODS

Patients
The protocol was approved by the Institutional Ethics Review Board at the National Cancer Center of Japan. Human leukocyte antigen (HLA)-A 0201, HLA-A 0206, and/or HLA-A 2402-positive patients with inoperable advanced pancreatic or biliary tract cancer were eligible for this study.
Other inclusion criteria were: (1) pathologically confirmed diagnosis of adenocarcinoma or adenosquamous carcinoma; (2) no previous history of treatment by GEM; (3) Eastern Cooperative Oncology Group Performance Status of 0 to 2; (4) expected survival of at least 2 months; (5) aged 20 years or more; (6) adequate main organ function; and (7) provision of written informed consent.
Exclusion criteria were as follows: (1) active infection; (2) severe complications such as heart failure, renal failure, hepatic failure, active gastric ulcer, gastric paralysis, or uncontrollable diabetes; (3) ascites or pleural effusion; (4) severe mental disorder; (5) metastasis to the central nervous system; (6) pregnancy or breast feeding; (7) interstitial pneumonia or pulmonary fibrosis; (8) myeloproliferative disease; (9) history of autoimmune disease; and (10) administration of immunosuppressive drug or corticosteroids.
Study Design
This study was an open-labeled, dose-escalation phase 1 study. The primary end point was evaluation of toxicity, safety, and optimal immunologic dose of combined GEM and WT1 vaccination, and determination of the recommended dose for the phase 2 study. The secondary end point was evaluation of response rate and progression-free survival. Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0), and treatment efficacy was determined according to the Response Evaluation Criteria in Solid Tumors.
GEM and WT1 vaccine were administered every 28 days as follows: intravenous infusion of GEM (1000 mg/m 2 ) on days 1, 8, and 15 with 1-week rest. Vaccine (0.1 mL) was injected intradermally into 6 areas (bilateral arms, 2 sites on the lower abdomen and femoral areas) biweekly on day 8 and day 22. Although the scheduled study period was 2 courses, treatment could be continued at the patient's request if there was no disease progression or serious adverse events.
The first vaccination dose (1 mg) was administered to 3 patients, and the dose was increased to the second dose level of 3 mg if no dose-limiting toxicity was observed. When no toxicity was observed in 6 patients who received the second dose level of 3 mg, the study was completed.
WT1 Vaccine Preparation
HLA-A02-restricted WT1 126-134 peptide (RMFP NAPYL) and HLA-A24-restricted WT1 235-243 peptide (CYTWNQMNL) were synthesized at good manufacturing practice grade by NeoMPS (San Diego, CA). WT1 peptides were dissolved in dimethyl sulfoxide (DMSO; Sigma, St Louis, MO) and 5% glucose. Solutions were emulsified with an equal weight of Montanide ISA-51VG adjuvant (Seppic, Paris, France).
Immunologic Analysis
Peripheral blood samples were obtained before vaccination and on day 15 of the first course, on days 1 and 15 of the second course, and on day 1 of the third and fourth courses. Surface marker analysis, multimer assay, and intracellular cytokine staining were performed on the day of sampling. Mixed lymphocyte and peptide culture (MLPC) was performed with the remaining blood preserved as peripheral blood mononuclear cells.
Delayed-type Hypersensitivity (DTH) Test
Delayed-type hypersensitivity (DTH) test was performed before the first vaccination in 20 patients, and after the fourth and tenth vaccinations, if possible. DTH was examined by intradermal injection of 30 mg WT1 peptide dissolved in 50 mL DMSO and saline as a negative control. DTH was measured in terms of maximum diameter of induration or erythema at the injection site at 48 to 72 hours after injection.
Surface Marker Analysis
Whole blood samples were incubated with monoclonal antibodies for 30 minutes at room temperature in the dark. Red blood cells were lysed using PharmLyse [Becton Dickinson (BD), San Diego, CA], and after being washed with Cell Wash (BD), cells were fixed (CellFix, BD) and acquired on a flow cytometer (FACSCalibur, BD). Analyses were performed using CellQuest software.
Multimer Assay
Allophycocyanin-conjugated pentamers and dextramers for WT1/HLA-A*02 (RMFPNAPYL) and WT1/HLA-A*24 (CYTWNQMNL), human immunodeficiency virus/HLA-A*02 (ILKEPVHGV), and human immunodeficiency virus/ HLA-A*24 (RYLRDQQLL) as negative controls, and cytomegalovirus (CMV)/HLA-A*02 (NLVPMVATV) and CMV/ HLA-A*24 (QYDPVAALF) as positive controls were purchased from Proimmune (Oxford, UK) or provided by Dako Instruments (Glostrup, Denmark).
Whole blood was stained with multimer for 15 minutes, followed by staining with CD8 peridinin chlorophyll protein complex, CD3 fluorescein isothiocyanate (FITC), and CCR7 phycoerythrin for 10 minutes at room temperature in the dark. Subsequent steps were the same as for surface marker analysis.
Intracellular Cytokine Staining
Whole blood (1 mL) was stimulated with 1.0 mM WT1 peptide, DMSO (negative control), or CMV lysates (positive control) for 6 hours at 371C, in the presence of 10 mg/mL CD28 and CD49d as costimulatory monoclonal antibodies. Breferdin A (Sigma) was added during the last 4 hours of stimulation. After 6 hours of incubation, samples were kept at 41C overnight and were then lysed, permeabilized, and washed. After staining with CD69 FITC, interferon-g (or interleukin-4) phycoerythrin, and CD3 allophycocyanin for 30 minutes in the dark, samples were washed, fixed, and acquired on a flow cytometer (FACSCalibur, BD).
MLPC
Peripheral blood mononuclear cells samples were thawed and washed with culture medium (10% fetal bovine serum in Roswell Park Memorial Institute medium). Cells were stimulated with WT1 peptide at a final concentration of 10 mg/mL or with DMSO as a negative control, and were cultured in a 96-well round-bottomed plate at 2 Â 10 5 cells/ well. Culture medium containing 100 U/mL interleukin-2 was added on days 2 and 9 or 10. Cultured cells were collected on days 10 to 14, washed and were stained with WT1-tetramer or negative tetramer, CD8 FITC and 7-aminoactinomycin D. Cells were analyzed on a flow cytometer. Results were defined as positive when 7-aminoactinomycin D-negative CD8-positive WT1-tetramer-positive cells were detected in WT1 culture wells, and no CD8-positive tetramer-positive cells were detected in negative controls.
Statistical Analysis
Overall survival and progression-free survival were calculated from the date of assignment into the study to the date of death or final follow-up and the date of disease progression. Overall survival estimates were calculated using the Kaplan-Meier method, and the survival curves were compared between primary disease arms using the logrank test. Wilcoxon-Mann-Whitney U test was used for the statistical analysis of the immunologic assays.
RESULTS
Patient Characteristics
Between November 2007 and September 2009, 25 patients (13 male and 12 female) were enrolled in this study. Patient characteristics are presented in Table 1 . The median age was 65 years (range: 30-79 y). Nine patients (36%) had inoperable advanced pancreatic cancer, 8 (32%) had gallbladder cancer, 4 (16%) had intrahepatic bile duct cancer, and 4 (16%) had extrahepatic bile duct cancer. One patient (4%) had previously received chemotherapy with an oral fluoropyridine (S-1), 6 (24%) had undergone surgery, whereas 11 (44%) had received biliary drainage. Eighteen patients (72%) were at clinical stage IV, and 7 (28%) were at stage III. Fourteen patients positive for HLA-A*2402 were treated with HLA-A24-restricted WT1 235-243 peptide, and 9 HLA-A*0201-positive and 2 HLA-A*0206-positive patients, including 4 patients positive for both HLA-A*0201 and HLA-A*2402, were treated with HLA-A02-restricted WT1 126 to 134 peptide. Seven patients were treated at the first dose level (1 mg/dose) of WT1 vaccine and 18 were treated at the second dose level (3 mg/dose).
Eighteen patients (72%) completed the protocol, and 7 patients (28%) left the study because of rapid disease progression (6 patients) or patient choice (1 patient). Fifteen patients continued compassionate combined GEM and WT1 vaccination therapy after completing the protocol.
Toxicity
As no dose-limiting toxicities were observed at the first dose level, the dose was increased to the second level after 3 patients each completed the HLA-02 and HLA-24 peptide administration at the first dose level. No dose-limiting toxicities were seen throughout the study.
Toxicities documented within the 2 months are shown in Table 2 . All patients experienced grade 1 or 2 skin reactions at the site of vaccination; redness and pruritus at the injection site were observed in 25 patients (100%), and induration was seen in 23 patients (92%). Although no patients dropped out of the study due to skin reactions, 2 patients (UPN10 and 19) elected to discontinue treatment because of skin reactions after study completion. In particular, 1 patient (UPN19) discontinued vaccination at 5 months as she developed skin ulcers after the tenth vaccination. Although she continued treatment with GEM alone after the appearance of ulcers, she developed new ulcerations at the injection sites 2 weeks later. Another patient (UPN10) developed severe induration, pruritus, and swelling at the injection site, and had swollen lymph nodes near the vaccination site after 8 months of treatment. Vaccination therapy was terminated at 9 months and treatment with GEM alone was continued because the disease was stable. Despite withdrawal of vaccination treatment, local reactions did not improve and itching, redness, and nodules remained for another 3 months.
Cytopenia, thought to be caused by GEM, was observed in all 25 patients, including 11 with grade 3 to 4 neutropenia and 3 patients with grade 3 anemia. Grade 1 to 2 gastrointestinal symptoms probably because of GEM, such as anorexia (52%), nausea (48%), and vomiting (12%), were also observed.
Clinical Response
Disease status was assessed at the end of the study based on tumor size and metastasis examined by computed tomography. Blood tests for tumor markers such as carcinoembryonic antigen and cancer antigen 19-9 were evaluated as reference data (not considered to be response criteria). The results showed that 15 of the 18 patients who completed the study had stable disease and 3 had progressive disease (PD).
The median survival time of all patients was 278 days: biliary tract cancer, 288 days (gallbladder cancer, 153 days; intrahepatic bile duct cancer, 384 days; and extrahepatic bile duct cancer, 301 days) and pancreatic cancer, 259 days (Fig. 1) . Disease control rate at 2 months was 89% for pancreatic cancer, 25% for gallbladder cancer, 100% for intrahepatic bile duct cancer, and 50% for extrahepatic bile duct cancer.
Survival did not significantly differ between patients who received HLA-A02-restricted and HLA-A24-restricted vaccine (P = 0.39) (Fig. 2) .
Immunologic Responses
No patients exhibited DTH reactivity at pretreatment. Two of the 20 patients showed positive DTH reactions after the fourth vaccination (UPN18 and 19), and 1 patient was positive after the tenth or twelfth vaccination (UPN18).
Surface marker analysis showed that CD14 + monocytes and 2 types of dendritic cells, CD123
+ and CD11c + , were significantly elevated whereas the absolute number of most immune cells decreased. (Table 3 ). WT1-specific T cells were not detectable in uncultured fresh whole blood on either dextramer or pentamer assay. Intracellular interferon-g production of peripheral lymphocytes stimulated by WT1 peptide was also not significant when compared with negative controls.
MLPC analysis was available from all patients before vaccination, from 20 patients after the second vaccination, from 16 patients after fourth vaccination, and from 9 patients after sixth vaccination or more (Table 4) . Positive results were observed at least once after vaccination in 65% (13 of the 20) of the patients. Representative results of MLPC analysis are shown in Figure 3 . Only 1 of 25 samples taken before vaccination showed WT1-specific T lymphocytes. The positivity rates for MLPC after the second, fourth, sixth, twelfth, and 30th vaccinations were 25% (5 of 20), 50% (8 of 16), 56% (5 of 9), 33% (2 of 6), and 100% (1 of 1), respectively. Two patients showed positive results for the first time after the sixth and twelfth vaccinations (UPN12 and 19), whereas in another 2 patients, WT1-specific lymphocytes were detected after the fourth vaccination, and these subsequently disappeared during repeated vaccination therapy (UPN1 and 22).
DISCUSSION
In this clinical phase 1 study, we evaluated the safety and efficacy of GEM and WT1 vaccine combination therapy in patients with advanced pancreatic or biliary tract cancer. This combination therapy was found to be safe with mild toxicity. No dose-limiting toxicities were observed during the study period. Hematopoietic toxicity occurred in all patients; however, the frequency and severity was comparable to that of GEM treatment alone. Grade 1 to 2 gastrointestinal toxicities, which were seen in approximately half of patients, were also considered to be a consequence of GEM toxicity. All other adverse events were of grade 1 and considered to be because of the primary disease. There was no apparent difference in adverse events between the HLA-A02 and HLA-A24-restricted peptide vaccines. Although some patients showed relatively good clinical outcomes during this study, the clinical efficacy of WT1 vaccine was not apparent from this study. One patient with intrahepatic bile duct cancer and another patient with extrahepatic bile duct cancer have continued receiving this combination therapy for 22 and 21 months, respectively, and the disease has remained stable. One patient with pancreatic cancer showed a reduction in tumor size at 3 months. However, overexpression of WT1 was not determined in this study, and it is likely that GEM exerted a major effect on this particular patient. GEM monotherapy showed far better survival than historical controls in the Japan Clinical Oncology Group 0506 phase 2 study for locally advanced pancreatic cancer, 24 and survival among patients treated in the 2000s, after the introduction of GEM in Japan, was significantly better than that of patients treated in the 1980s and 1990s. 25 Six patients could not complete this study because of rapid disease progression. The reason for high PD rate in gall bladder cancer was that most of the patients with gall bladder cancer enrolled in this study had highly advanced disease, whereas 2 patients with relatively well-controlled disease have survived for years. Vaccination therapy seems to have a smaller effect on those with rapid PD, possibly because it takes at least 2 months to induce antitumor effects by vaccination. Administration of vaccine at earlier disease states when adequate immunity is preserved thus seems to be necessary. Vaccine therapy in combination with other treatment modalities that do not suppress host immunity, such as radiation therapy, may also improve efficacy.
Two cases who continued the therapy after the study period showed severe local skin reactions. These severe skin reactions have not been reported earlier with WT1 vaccine therapy, and are considered to be because of the additive effects of GEM on WT1 peptide. Surface marker analysis of peripheral blood showed similar results to our earlier study on the immunologic effects of GEM, 26 confirming an increase in monocytes and dendritic cells during GEM administration. The increase in dendritic cells may have had an effect on local inflammation at the injection sites in the present cases. It was difficult to predict the patients who were likely to develop severe local reactions, as the results of immunomonitoring were not distinguishable from those FIGURE 1. Kaplan-Meier estimates of overall survival for biliary tract cancer and pancreatic cancer. Median survival time for biliary tract cancer (n = 16) was 288 days and for pancreatic cancer (n = 9) was 259 days. There were no significant differences between the 2 curves (P = 0.78). of other patients.
27 WT1-specific lymphocytes were detectable by MLPC for the first time after 12 vaccinations in the first patient (UPN19), and no WT1-specific lymphocytes were detected throughout the course in the other patient (UPN10). Nevertheless, it is probable that the features of local immunologic status may differ from those of circulating lymphocytes in the peripheral blood.
No WT1-specific lymphocytes were detected on multimer staining in noncultured fresh whole blood. As WT1-specific lymphocytes were detected by MLPC methods, it is likely that the frequency of circulating WT1-specific lymphocytes was very low and below the detection level without expansion. WT1 vaccination is thought to have an expansion effect on precursor WT1-specific lymphocytes, as only 1 patient showed positive results before vaccination, whereas 65% of patients showed positive results at least once after vaccination therapy. However, we were unable to show an apparent relationship between the therapeutic effects and the emergence of WT1-specific lymphocytes in this study. Furthermore, induction of WT1-specific lymphocytes required a long period of time in some patients, whereas WT1-specific lymphocytes disappeared during repetition of this combination therapy in some patients. Disappearance of WT1-specific T lymphocytes may be because of T-cell anergy. The optimal immunologic dose of WT1 vaccine may therefore differ among individual patients. The WT1 peptide dose used in this study was larger than those used in other studies. The second dose level of 3 mg is the maximum dose that can be emulsified in a final volume of 600 mL, which we consider to be the maximum practical and realistic volume that can be injected intradermally at 6 sites (100 mL/site). The vaccine was injected intradermally to enhance immune reactivity, as the Langerhans cells that serve as antigen-presenting cells are distributed in the spinous layer of the epidermis. We were unable to determine the optimal dose for the WT1 vaccine, as the maximum tolerable dose may not be equivalent to the optimal dose, and a dose escalation study, as used in chemotherapy, is not applicable to cancer immunotherapy; thus, development of a realistic immunomonitoring system to determine the optimal vaccine dose is necessary.
Two types of 9-mer peptide, HLA-A02 and HLA-A24-restricted WT1 peptides, were used in this study. These peptides may be applied to the worldwide population, as HLA-A0201 and A2402 accounts for 57% of the Asian population, 56% of White population, and 17% of the African population. 28 The peptide earlier reported as HLA-A0201 restricted was applied to both HLA-A0201 and HLA-A0206 patients, as antigen-specific T cells against this peptide have been detected in relation to graft-versus-tumor effects in HLA-A0206-positive patients who had undergone hematopoietic stem cell transplantation in our earlier studies, thus suggesting the potency of this antigen in HLA-A0206 patients. 29 The HLA-binding motif prediction also showed that this peptide had a common anchor site with HLA-0206, which suggests that it could be applied to HLA-A0206 patients. 30 In conclusion, although the aim of this study was to assess the safety of the combination of WT1 peptide vaccine and GEM in a small population, our observations indicated that this therapy is safe for patients with advanced pancreatic or biliary tract cancer and may provide longterm survival benefits in some patients. 
